• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    RXi Pharmaceuticals Corporation (RXII)

    -NasdaqCM
    2.22 Up 0.05(2.30%) Apr 29, 4:00PM EDT
    ProfileGet Profile for:
    RXi Pharmaceuticals Corporation
    257 Simarano Drive
    Suite 101
    Marlborough, MA 01752
    United States - Map
    Phone: 508-767-3861
    Fax: 508-767-3862
    Website: http://www.rxipharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:15

    Business Summary 

    RXi Pharmaceuticals Corporation, a clinical-stage RNAi company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and a Phase I/II clinical trial in retinal scarring. It is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, an formulation of diphenylcyclopropenone, which is in Phase II clinical trial for the treatment of various disorders, such as warts, alopecia areata, non-malignant skin tumors, and cutaneous metastases of melanoma. In addition, the company is developing dermal scarring and wart programs with its sd-rxRNA technology. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on RXi Pharmaceuticals Corporation

    Key Executives 
     PayExercised
    Dr. Geert Cauwenbergh Ph.D., Med.Sc., 62
    Chief Exec. Officer, Pres, Acting Chief Financial Officer, Director and Member of Nominating & Governance Committee
    588.00K0.00
    Dr. Pamela A. Pavco Ph.D., 60
    Chief Devel. Officer
    468.00K0.00
    Ms. Caitlin Kontulis , 30
    Principal Accounting Officer, Director of Fin., Sec. and Controller
    N/AN/A
    Dr. Karen Bulock Ph.D.,
    VP of Research
    N/AN/A
    Dr. Lyn Libertine M.D.,
    VP of Medical Affairs & Safety Assessment
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders